115
Participants
Start Date
August 31, 2006
Primary Completion Date
January 31, 2009
Study Completion Date
February 24, 2009
Pralatrexate Injection
Pralatrexate 30 mg/m2 via IV push over 3-5 minutes for 6 weeks in a 7 week cycle.
Cliniques Universitaire Saint-Luc, Brussels
Cliniques Universitaires UCL, Yvoir
Memorial Sloan-Kettering Cancer Center, New York
New York Presbyterian Hospital, New York
Columbia University Medical Center, New York
University of Rochester Cancer Center, Rochester
Fox Chase Cancer Center, Philadelphia
CHU DIJON - Hôpital d'enfant, Dijon
Emory University, Atlanta
Ospedale Sant'Orsola - Policlinico Sant'Orsola, Bologna
CHU Nantes - Hôtel Dieu, Paris
CHU Robert Debré, Reims
University of Iowa Hospitals and Clinics, Iowa City
University of Chicago Hospital, Chicago
Washington University School of Medicine, St Louis
Centre Hospitalier Lyon Sud, Pierre-Bénite
Tulane Cancer Center, New Orleans
CHU Saint Louis, Paris
UT MD Anderson Cancer Center, Houston
Nevada Cancer Institute, Las Vegas
City of Hope National Medical Center, Duarte
CHU Henri Mondor, Créteil
Fred Hutchinson Cancer Research Center, Seattle
University of California at Los Angeles, Los Angeles
Yale University School of Medicine, New Haven
Dana-Farber Cancer Institute, Boston
The Cancer Center at Hackensack University Medical Center, Hackensack
British Columbia Cancer Agency, Vancouver
Princess Margaret Hospital, Toronto
CHU Nice - Hôpital de l'Archet 1, Nice
St. Georges Hospital, London
The Royal Marsden NHS Foundation Trust, Sutton
Lead Sponsor
Acrotech Biopharma Inc.
INDUSTRY